

Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population

**David MG Halpin^{1,2}, Hilda JI de Jong², Victoria Carter², Derek Skinner²,
David Price^{2,3}**

¹Royal Devon & Exeter Hospital, Exeter, UK, ²Observational and Pragmatic Research Institute, Singapore, ³Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK



Inclusion Criteria

Patients with a recorded diagnosis of COPD on 1/1/2014 in the Optimum Patient Care Research Database (**Cohort 1**) & patients newly initiated on maintenance therapy (**Cohort 2**) in 2014 with a two-year follow-up were studied.

Patients were included if they met the following criteria:

- a diagnostic code (Quality Outcomes Framework (QOF) defined) for COPD
- registered with a general practitioner (GP) for at least one year before 1/1/2014 (**cohort 1**) or the date of the first prescription of maintenance treatment for COPD (**cohort 2**).
- a continuous medical record data between 1/1/2014 and 31/12/2016.

Initiating maintenance treatment for COPD was defined as the first prescription in the year 2014 (the index date year) of: long-acting beta agonists (LABA); long-acting muscarinic antagonists (LAMA); inhaled corticosteroids (ICS), or combination therapies of LABA, LAMA and ICS (LAMA/LABA, ICS/LABA, ICS/LAMA, LABA/LAMA/ICS).

Both cohorts had data on the number of exacerbations in the previous 12 months, mMRC & FEV1 in the year 2014.

Comorbidities in Established COPD Patients

Comorbidities in Cohort 1. All patients with diagnosis of COPD on 1/1/2014 (n=6438)	
C n=816 (12.7%) Diabetes mellitus 15.3% Osteoporosis 7.6% Cardiovascular disease 9.8% Heart failure 10.9% Pneumonia 1.8% Anxiety/Depression 20.2% ?	D n=925 (14.4%) Diabetes mellitus 17.6% Osteoporosis 9.6% Cardiovascular disease 12.8% Heart failure 1.7% Pneumonia 1.3% Anxiety/Depression 29.0% ?
A n=2941 (45.7%) Diabetes mellitus 13.5% Osteoporosis 6.0% Cardiovascular disease 8.7% Heart failure 1.1% Pneumonia 10.7% Anxiety/Depression 16.7% ?	B n=1756 (27.3%) Diabetes mellitus 18.3% Osteoporosis 7.9% Cardiovascular disease 10.5% Heart failure 1.7% Pneumonia 10.5% Anxiety/Depression 21.3% ?

Comorbidities in New COPD Patients

Comorbidities in Cohort 2. Patients initiating maintenance therapy 1/1/2014-31/12/2014 (n=701)	
C n=104 (14.8%) Diabetes mellitus 2.5% Osteoporosis 1.9% Cardiovascular disease 1.5% Heart failure 1.9% Pneumonia 1.0% Anxiety/Depression 25.0% ?	D n=66 (9.4%) Diabetes mellitus 3.6% Osteoporosis 6.1% Cardiovascular disease 9.1% Heart failure 3.0% Pneumonia 3.0% Anxiety/Depression 19.7% ?
A n=324 (46.2%) Diabetes mellitus 3.3% Osteoporosis 2.5% Cardiovascular disease 3.6% Heart failure 0.9% Pneumonia 0.6% Anxiety/Depression 17.3% ?	B n=207 (29.5%) Diabetes mellitus 18.4% Osteoporosis 7.7% Cardiovascular disease 12.1% Heart failure 2.4% Pneumonia 1.9% Anxiety/Depression 19.8% ?